tbuckley/cabot-search huggingface dataset:
Adoptive transfer of vitiligo after allogeneic peripheral blood stem cell transplant
Authors: A. Campbell-Fontaine, S. Ericson
Journal: Journal of Clinical Oncology (2004)

6652 Background: Vitiligo is an acquired condition of skin depigmentation that affects less than 1% of the general population. The exact etiology is unknown, however, the condition has been found in association with autoimmune disorders such as autoimmune thyroid disease and myasthenia gravis. Methods: We describe the case of a fifty-two year old female with relapsed acute myelogenous leukemia. After reinduction chemotherapy, which resulted in complete remission, the patient was treated with high dose chemotherapy followed by a matched sibling donor allogeneic stem cell transplant. Eighteen months after transplant, the patient was noted to have diffuse patchy areas of depigmentation of her skin. She had dry skin, but no other clinical findings suspicious for graft-versus-host disease (GVHD). The patient had a punch biopsy of a skin lesion and also testing to rule out cytomegalovirus (CMV) infection. Results: A skin biopsy showed minimal perivascular lymphocytic infiltrates with minimal basal vacuolization. Immunostains revealed decreased numbers of melanocytes within the epidermis, compatible with vitiligo, and S100 and Mart1 stains supported this interpretation. CMV antigenemia testing showed no evidence of CMV-infected cells. Conclusions: Several diseases, including vitiligo, have been found to be adoptively transferred through allogeneic stem cell/bone marrow transplantation. In previous case reports, cytomegalovirus infection as well as graft-versus-host disease were cited as predisposing factors to the development of vitiligo post-transplant. All of these cases were noted three to nine months post-transplant. We have not found reports of patients developing vitiligo post-transplant in a delayed fashion, as our patient did. The patient had previous episodes of reactivation of CMV and was treated for both acute and chronic GVHD. We concluded that both of these conditions could have played a role in the development of vitiligo, although the condition developed eighteen months post-transplant. No significant financial relationships to disclose.
Anomalous first rib as a cause of the thoracic outlet syndrome
Authors: H. Siderys
Journal: JAMA (1967)

THE THORACIC outlet syndrome is a well-known clinical entity. Reports of neurovascular compression by a cervical rib, the scalenus anticus muscle, deformity of the clavicle, and other anatomical variations have appeared frequently. Although anomalous first ribs also distort the thoracic outlet, they have only rarely appeared in the literature as a cause of the syndrome. Two cases of thoracic outlet syndrome associated with anomalous first ribs are presented. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 32-year-old white man was admitted to the hospital because of pain in the left shoulder and hand. He stated that when he was 20 years old he became aware of a painful mass in the left supraclavicular space. This mass was hard and tender, and pain in the region of the mass was associated with pain in the left axilla and along the medial aspect of his left arm. The pain descended down his left forearm
Effects of Methylcholanthrene in Pregnant Mice&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Effects of Methylcholanthrene in Pregnant Mice Get access L. C. Strong, L. C. Strong Search for other works by this author on: Oxford Academic PubMed Google Scholar W. F. Hollander W. F. Hollander Department of Anatomy, Yale University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 8, Issue 2, October 1947, Pages 79–82, https://doi.org/10.1093/jnci/8.2.79 Published: 01 October 1947 Article history Published: 01 October 1947 Received: 23 October 1947
Innovations for JACI 2006
Authors: Henning Allmers, Leonard Bacharier, St Louis, Gary Bannon, Donald Beezhold, Wva Bruce Bender, Jonathan Bernstein, Albrecht Bufe, Wesley Burks, Donald Cockcroft, Canada Ronina Covar, Adnan Custovic, Azzeddine Dakhama, Stephen Dreskin, Ricki Helm, Little Rock, Allen Kaplan, Chris Kepley, Eric Macy, San Diego, Jean-Luc Malo, Bruce Mazer, Deborah Meyers, Natalija Novak, Stephen Rosenfeld, Louis Rosenthal, Hirohisa Saito, Ulla Riitta, Seppa ¨la ¨, Jonathan Spergel, John Steinke, David Stempel, Susan Tarlo
Journal: Journal of Allergy and Clinical Immunology (2006)
Protecting the uninsured. Use of state risk-pools. Council on Medical Service
Journal: JAMA (1988)

Society already bears a large part of the costs attributable to the lack of adequate health expense protection for the uninsured, whether through lost manhours and productivity resulting from the postponement of needed medical attention or through defraying the economic burden of uncompensated care. The question, therefore, is not whether such costs should be met, but how they can be met in a way that best maintains and preserves the health of the needy while apportioning this cost equitably over all sectors of the American economy. The Council on Medical Service believes that the establishment of state risk-pools with the modifications suggested in this report, coupled with the other AMA policy initiatives identified at the beginning of this report, will go a long way toward meeting the needs of the uninsured population.
Reduced Cadmium Levels in Human Kidney Cortex in Sweden
Authors: Lennart Friis, Lars Petersson, Christer Edling
Journal: Environmental Health Perspectives (1998)

Environmental pollution with the nephrotoxic metal cadmium is considered a potential health risk for the general population. In 1976 it was reported that the cadmium concentration in human kidney cortex in Sweden had increased in parallel with increasing levels in soil and grain during the twentieth century. Since the cadmium concentration in farming lands is still increasing, the present study was undertaken to further elucidate whether the cadmium concentration in the kidney is still increasing. Kidney cortex biopsies were collected at 171 autopsies of victims to sudden and accidental death during 1995 and 1996, and the cadmium concentrations were determined and compared with previously published Swedish data obtained from forensic autopsies. The geometric mean cadmium concentration in kidney cortex in subjects 40 years of age and younger was about 40% of the concentration found in the 1970s, while the reduction was less pronounced among older people. The highest individual concentration of cadmium was 41.5 microg/g wet weight (ww). The geometric mean concentration was less than 14 microg/g ww at ages around 50 years of age, when the cadmium concentration in kidney cortex is highest, as compared with approximately 20 microg/g ww in the 1970s. There was also a reduction in cadmium concentrations among nonsmokers; thus, a decrease in tobacco smoking in Sweden during the last decades is not the only explanation for the reduction of cadmium in the kidney cortex. Other reasons for this reduction could be changes in dietary habits and reduced cadmium contamination from Swedish industries.
Thrombolysis for Acute Stroke
Authors: Lowell Wood
Journal: JAMA (1996)

<h3>To the Editor.</h3> —The Original Contribution reporting results from the European Cooperative Acute Stroke Study (ECASS)<sup>1</sup>begs at least three basic questions. The first concerns the puzzling statement regarding recombinant tissue plasminogen activator (rt-PA): "Herniation from space-occupying edema was more frequent in the rt-PA—treated group. These data do not support the hypothesis that successful recanalization is followed by a significantly increased risk of brain edema that may require aggressive therapy for increased intracranial pressure." The fundamental objective of the rt-PA treatment in the ECASS was declared to be recanalization, and this was apparently achieved to a significant extent. If brain edema was observed to occur more frequently in the treated group—and the data of Table 5 in the article declare that "Edema, herniation" resulted in at least 50% greater differential neurological mortality in the target population at all time points, as well as overall—how is it that a hypothesis
Revue Médicale de Liège
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ESSENTIAL HYPERTENSION
Authors: Harry Mandelbaum
Journal: JAMA (1942)

<h3>To the Editor:—</h3> Reports of toxic reactions and an occasional death following thiocyanate therapy in hypertension tend to emphasize the need for care in the selection of patients for treatment and in their supervision while receiving this drug. Many of the pharmacologic properties of thiocyanates have been reviewed in the several publications by M. H. Barker: 1. The content of the thiocyanates in the blood is an index of the thiocyanate content of the tissues, and this depends on the intake and rate of excretion through the kidneys. 2. The rate of excretion of thiocyanates from the body is extremely variable. The only correlation is a tendency for the cyanate clearance to be depressed when the urea clearance is low (The Journal, March 25, 1939, p. 1120). Thus an important contraindication to the use of thiocyanates in vascular hypertension is seriously impaired renal function. The fatal outcome in the case
03.23 Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy
Authors: Garyfalia Papadaki, Panagiota Goutakoli, Joachim R Grün, Andreas Grützkau, Antonios Fanouriakis, George A Pavlopoulos, Ioannis Iliopoulos, George Bertsias, Dimitrios Boumpas, Prodromos Sidiropoulos, Panayotis Verginis
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background/objectives</h3> Reestablishing immune tolerance and long term suppression represent major therapeutic goals in rheumatoid arthritis (RA). Our laboratory previously demonstrated that plasmacytoid dendritic cells (pDCs) from RA patients in remission have the ability to induce IL-10 producing regulatory T cells (Tregs) <i>in vitro</i>. However the molecular mechanism of RA pDC-mediated Treg induction remains elusive. Herein, we sought to identify novel targets of RA pDCs that contributes to the induction of tolerance and might lead to remission. <h3>Materials/methods</h3> pDCs were isolated from peripheral blood of RA patients responding to anti-TNF therapy (remission based on disease activity score DAS28 &lt;5.1) and healthy control subjects and DNA microarrays were performed. Flow cytometry and real time PCR were used to verify the expression of de-regulated genes in pDCs. Finally, <i>in vitro</i> cultures of pDCs activated with CpG B were performed to assess the functional importance of these gene signatures. <h3>Results</h3> pDCs from RA patients (n=5) exhibited a differential gene signature (6741 deregulated genes) compared to pDCs from healthy controls (n=5). Notably, IL-6 receptor (IL-6R) gene, exhibited increased expression levels in pDCs isolated from RA patients compared to healthy pDCs. We verified these results using flow cytometry for the surface expression levels of IL-6 receptor in a subsequent cohort of patients responding to therapy (n=3) vs healthy. Moreover, in functional experiments assessing IL-6R activation, coculture of healthy pDCs with CpG B in the presence or absence of recombinant IL-6, revealed that pSTAT3 levels were increased in pDCs cultured in the presence of IL-6. Cytokine expression studies (IFN-α, β, TNF-α, IL-6) are in progress to address the role of pDCs upon IL-6 signalling. The functional importance of the previous findings will be addressed in coculture experiments of IL-6 stimulated pDCs with CD4<sup>+</sup>CD25<sup>-</sup> T cells isolated from cord blood and monitor T cell proliferation based on dilution of CFSE staining. <h3>Conclusions</h3> We found that pDCs from RA patients in remission display increased IL-6R expression levels and IL-6 signalling pathway is induced in healthy pDCs in the presence of IL-6. This novel finding that may drive pDCs towards a previously described tolerogenic phenotype, need to be further addressed.
International Association of Cancer Victors and Friends, Inc
Journal: CA A Cancer Journal for Clinicians (1989)

After study of the literature and other available information, the American Cancer Society has found no evidence that methods of treatment promoted by the International Association of Cancer Victors and Friends, Inc. (IACVF), would result in objective benefit in the treatment of cancer in human beings. Lacking such evidence, the American Cancer Society strongly urges individuals with cancer not to seek treatment based on the recommendations of IACVF.
Influenza A (H3N2) Variant Virus-Related Hospitalizations—Ohio, 2012
Journal: JAMA (2012)

Since July 2012, 305 cases of infection with influenza A (H3N2) variant (H3N2v) virus containing the influenza A (H1N1)pdm09 M gene have occurred in multiple U.S. states, primarily associated with swine exposure at agricultural fairs. In Ohio, from July 28 to September 25, 2012, a total of 106 confirmed H3N2v cases were identified through enhanced surveillance. Whereas most H3N2v patients experienced mild, self-limited influenza-like illness (ILI), 11 of the Ohio patients were hospitalized, representing 69% of all H3N2v hospitalizations in the United States. Of these hospitalized H3N2v patients, six were at increased risk for influenza complications because of age or underlying medical conditions, including the only H3N2v-associated fatality reported in the United States to date. This report summarizes the epidemiology and clinical features of the 11 hospitalized H3N2v patients in Ohio. These findings reinforce the recommendation for persons at high risk for influenza complications to avoid swine exposure at agricultural fairs this fall. In addition, persons not at high risk for influenza complications who wish to reduce their risk for infection with influenza viruses circulating among pigs also should avoid swine and swine barns at agricultural fairs this fall.
Reply
Authors: P. McCullagh, J.M. Theaker
Journal: British Journal of Dermatology (1994)

Journal Article Reply Get access P. McCullagh, P. McCullagh Department of Histo pathology, Level E, South Academic Block, General Hospital, Southampton S09 4XY. U.K. Search for other works by this author on: Oxford Academic Google Scholar J.M. Theaker J.M. Theaker Department of Histo pathology, Level E, South Academic Block, General Hospital, Southampton S09 4XY. U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 130, Issue 1, 1 January 1994, Pages 133–134, https://doi.org/10.1111/j.1365-2133.1994.tb06907.x Published: 01 January 1994
Stable Expression And Somatic Hypermutation Of Antibody V Regions In B-Cell Developmental Pathways
Authors: C Kocks
Journal: Annual Review of Immunology (1989)

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, ...Read More
Two New Projects to Help Native Americans End Substance Abuse and Domestic Violence
Authors: Mike Mitka
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0179 The specific inhibitor of RORγT transcriptional activity and TH17 polarization digoxin reduces the severity of adjuvant-induced arthritis
Authors: R. Cascão, B. Vidal, J.E. Fonseca, L.F. Moita
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> We have previously reported an increase of interleukin (IL)-17 levels during the first weeks of rheumatoid arthritis (RA) onset. <h3>Objectives</h3> Our main goal here was to investigate whether administration of digoxin, a specific inhibitor of Th17 cells polarization, is able to attenuate inflammation in a rat model of adjuvant-induced arthritis (AIA). <h3>Methods</h3> Digoxin was administered to AIA rats in the early phase (4 days after disease induction) or in the established phase of arthritis (11 days after disease induction). The inflammatory score, paw perimeter and body weight were evaluated during the period of treatment. Rats were sacrificed after 19 days of disease evolution and paw samples were collected for histological and immunohistochemical evaluation. <h3>Results</h3> We found that digoxin administration significantly suppressed joint inflammation if administrated in the early phase of disease course. The histological and immunohistochemical evaluation revealed that digoxin treatment was not efficient in inhibiting the infiltration of immune cells within the joint, but it was able to reduce local immune cells proliferation, if administrated in the early phase of arthritis. <h3>Conclusions</h3> Early inhibition of Th17 polarization ameliorates AIA but does not inhibit immune cell infiltration into the joints. <h3>Disclosure of Interest</h3> None Declared
Pulmonary Phthisis; Its Diagnosis, Prognosis and Treatment.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract LB-095: Aurora-A is elevated in cancer cells due to inactivation of EF1A2-PTEN-GSK3b regulated late S-G2 phase specific degradation pathway
Authors: Warapen Treekitkarnmongkol, Luisa Maren Solis, Kazuharu Kai, Kaori Sasai, Ignacio I. Wistuba, Aysegul A. Sahin, Kwong K. Wong, Alastair M. Thompson, Yoshimi Jltsumori, Jonathan M. Lee, Lidong Qin, Tasneem Bawa-Khalfe, Roland Rad, Catherine M. Abbott, Hiroshi Katayama, Subrata Sen
Journal: Cancer Research (2019)

Abstract Elevated expression of Aurora kinase-A oncoprotein is detected in a subset of human cancers across different organ sites. The mechanism(s) underlying over expression of the protein in cancer cells have not been well elucidated. This study demonstrates that inactivation of a novel mechanism of EF1A2 regulated PTEN-GSK3β-SCF complex mediated Aurora-A protein degradation pathway in S-G2 phases of mitosis leads to enhanced stability/steady state level of Aurora-A in cancer cells. EEF1A2 regulates interaction of Aurora-A with activated PTEN, GSK3β, Neddylated CUL1 and FBXW7, promoting ubiquitination mediated degradation of Aurora-A that is rescued in EEF1A2 knockdown cells. Ectopic expression of EEF1A2, on the other hand, enhances formation of the complex with GSK3β mediated inactivating phosphorylation and reduction in Aurora-A protein, recapitulating the S-G2 phase events. Genetic ablation of EEF1A2 and PTEN in both in vitro cell lines and in vivo mouse models validated the results. Aurora-A over expressing mouse models of mammary carcinoma and human breast cancer tissue samples also corroborated the findings. Therapeutic targeting of PTEN-GSK3β-AKT pathway may, therefore, be effective in treating a subset Aurora-A over expressing cancers. Citation Format: Warapen Treekitkarnmongkol, Luisa Maren Solis, Kazuharu Kai, Kaori Sasai, Ignacio I. Wistuba, Aysegul A. Sahin, Kwong K. Wong, Alastair M. Thompson, Yoshimi Jltsumori, Jonathan M. Lee, Lidong Qin, Tasneem Bawa-Khalfe, Roland Rad, Catherine M. Abbott, Hiroshi Katayama, Subrata Sen. Aurora-A is elevated in cancer cells due to inactivation of EF1A2-PTEN-GSK3b regulated late S-G2 phase specific degradation pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-095.